Autism

Long-Acting Liquid Methylphenidate for Treating ADHD in Intellectually Capable Adults with Autism Spectrum Disorder

AA Posted new AIA, ADHD and Comorbidity, ADHD Medications / By Stephen V. Faraone, PhD

A team from Harvard Medical School and Massachusetts General Hospital conducted a six-week open-label trial of liquid-formulation extended-release methylphenidate (MPH-ER) to treat ADHD in adults with high-functioning autism spectrum disorder (HF-ASD). ASD is a lifelong disorder with deficits in social communication and interaction and restricted, repetitive behaviors. Roughly half of those diagnosed with ASD also …

Long-Acting Liquid Methylphenidate for Treating ADHD in Intellectually Capable Adults with Autism Spectrum Disorder Read More »

We train health care professionals and
the public about ADHD in Adults
with the latest evidence-based content
from International Experts.

Program Committee: Stephen V. Faraone, PhD, Program Director;
Lenard Adler, MD, David Goodman, MD, Co-Chairs, APSARD Education Committee;
Jonathan Marx, MBA, Media and Marketing Director

Long-Acting Liquid Methylphenidate for Treating ADHD in Intellectually Capable Adults with Autism Spectrum Disorder

We train health care professionals and the public about ADHD in Adults with the latest evidence-based content from International Experts.

Program Committee: Stephen V. Faraone, PhD, Program Director; Lenard Adler, MD, David Goodman, MD, Co-Chairs, APSARD Education Committee; Jonathan Marx, MBA, Media and Marketing Director

Autism

We train health care professionals and
the public about ADHD in Adults
with the latest evidence-based content
from International Experts.

Program Committee: Stephen V. Faraone, PhD, Program Director;
Lenard Adler, MD, David Goodman, MD, Co-Chairs, APSARD Education Committee;
Jonathan Marx, MBA, Media and Marketing Director